Evogene (NASDAQ:EVGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Trading Up 2.0 %

NASDAQ:EVGN opened at $0.70 on Tuesday. The company’s 50-day moving average price is $0.81 and its 200-day moving average price is $0.73. The company has a market cap of $28.85 million, a P/E ratio of -1.32 and a beta of 1.49. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.73 million. During the same period last year, the firm posted ($0.07) earnings per share.

Institutional Investors Weigh In On Evogene

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Walleye Capital LLC purchased a new stake in shares of Evogene in the 3rd quarter valued at approximately $303,000. Silverarc Capital Management LLC grew its holdings in shares of Evogene by 3,000.0% in the third quarter. Silverarc Capital Management LLC now owns 3,100,000 shares of the biotechnology company’s stock valued at $1,818,000 after purchasing an additional 3,000,000 shares in the last quarter. BNP Paribas Arbitrage SNC grew its holdings in shares of Evogene by 265.4% in the second quarter. BNP Paribas Arbitrage SNC now owns 26,700 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 19,393 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Evogene by 31.8% in the first quarter. Renaissance Technologies LLC now owns 118,193 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 28,493 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Evogene by 49.7% in the first quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 67,867 shares in the last quarter. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.